Dr. Matthew S. Davids MD, MMSc

Matthew S. Davids, MD, MMSc, is an Associate Professor of Medicine at Harvard Medical School and Director of Clinical Research in the Division of Lymphoma at Dana-Farber Cancer Institute in Boston, Massachusetts. He is also an Attending Physician in the Division of Lymphoma at Dana-Farber as well as Associate Director of the Center for Chronic Lymphocytic Leukemia, and attends on the inpatient hematologic malignancies service at Brigham and Women’s Hospital.

Dr. Smith received his medical degree from Yale University School of Medicine in New Haven, Connecticut. He completed his internship, residency, and assistant chief residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology at Dana-Farber/Partners CancerCare, and a Master of Medical Science (MMSc) degree at Harvard Medical School.

Dr. Davids has an active translational research program in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma focusing on studying apoptosis (in particular Bcl-2 biology) in his laboratory, and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of his work has focused on the clinical development of new therapeutic regimens in CLL utilizing combinations of targeted inhibitors of Bcl-2, B cell receptor pathway kinases, and other novel agents, as well as utilizing checkpoint blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse after allogeneic hematopoietic cell transplantation.